跳至主要内容
临床试验/NCT02619123
NCT02619123Unknown不适用

Tailored Screening for Breast Cancer in Premenopausal Women. A Translational, Randomized Population-based Trial

Cancer Prevention and Research Institute, Italy5 个研究点 分布在 1 个国家目标入组 33,200 人开始时间: 2013年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
33,200
试验地点
5
主要终点
Comparison of cumulative incidence of interval cancer cases by arm and by density group

研究概览

简要总结

The Tailored Breast Screening Trial (TBST) is a population-based, non-inferiority randomised trial aimed at evaluating the impact of tailored screening strategies addressed to premenopausal women, by using breast density as indicator of risk.

44-45 years old women will be enrolled and invited to undergo a digital mammography. Women are then randomly allocated in two arms. In the intervention arm, women will receive a tailored screening strategy according to breast density.

The aim of this study is to assess the impact of a longer screening interval and the reduction of side effects for premenopausal women.

详细描述

Introduction

the Tailored Breast Screening Trial (TBST) is a population-based, non-inferiority randomised trial aimed at evaluating the impact of a change in the screening protocol in a service screening practice. "Tailored" means that the use of a breast density classification allocates women to a longer interval, decreasing the number of screening rounds in the 45-50-year age range. Density of the breast at the baseline is considered as an indicator of risk and also as a masking factor. The aim of this study is to assess the impact of a longer interval and the reduction of side effects for women allocated to the intervention group. In this study, any further intervention is offered to high-density women who are followed-up according to the usual care interval, since the study aimed at decreasing the screening burden.

Methods 44- 45 years old women resident in the screening centre catchment area will be invited to attend for mammography screening and will be asked for informed consent in order to be included in the study. After the enrolment, they will receive a high quality digital mammography; two views and breast density will be classified according with the BI-RADS classification. Women are randomly allocated either to an usual care group or to the intervention group. In the intervention group, women with a dense breast (3-4 categories in BI-RADS) will be invited again after 1 year, while the lower-density group in the intervention arm will be invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme. Density of the breast will be read by 2 readers, and controversies will be solved by a consensus. Allocation of women is blinded to the mammography readers.

EXPECTED RESULTS: the outcomes are: 1. cumulative incidence of interval-cancer cases by intention to treat grouping and by density group, aimed at assessing the non inferiority of screening performance; 2. cumulative incidence of T2+/node-positive status breast cancer cases between arms and by protocol. Screening performance parameters will be evaluated at each screening round. Interim and outcome analysis are expected at 3 and 6 years average follow-up, respectively, starting from the beginning of the screening.

SAMPLE SIZE: the non-inferiority limit is derived from the accepted level of interval cancers in women 50-69 years, which was considered acceptable by the European Community Guidelines. Assuming a 70%BI-RADS 1-2 at the baseline on the basis of the digital mammography experience, the estimated sample size with a power of 90% is 16,596 women per arm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Screening
盲法
Single (Investigator)

入排标准

年龄范围
44 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •women 44-45 years old resident in the screening area

排除标准

  • •previous diagnosis of invasive or in situ breast cancer
  • •women with family high risk for breast cancer
  • •previous diagnosis of other cancers in the last 5 years
  • •early menopause women or in hormone replacement therapy

研究组 & 干预措施

invitation to mammography screening

Active Comparator

44-45 years old women in this arm are invited to attend for a mammography screening every 1 year. After the age of 50, all women will continue to be screened in the usual service screening programme.

干预措施: Annual invitation to mammography (Other)

invitation to tailored screening

Experimental

44-45 years old women in this arm with a dense breast (3-4 categories in BI-RADS) at the baseline mammography are invited again after 1 year, while the lower-density group in the intervention arm are invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme.

干预措施: Tailored screening according to breast density (Other)

结局指标

主要结局

Comparison of cumulative incidence of interval cancer cases by arm and by density group

时间窗: three and six years

An "interval cancer" is, according to European guidelines for quality assurance, a primary breast cancer which is diagnosed in a woman who had a screening test negative for malignancy within a time period equal to the screening interval. Interval cancers will be retrieved by linking the cancer registry and screening archive. The "cumulative incidence of interval cancers" is the number of interval cancers divided by the number of screened women

Comparison of cumulative incidence of T2+/node-positive status breast cancer cases by arm and by density group.

时间窗: three and six years

The "cumulative incidence of T2+/N+ breast cancer" is the number of cancers T2+/N+, regardless the modality of detection (screen-detected, interval cancer, etc.), divided by the number of screened women

次要结局

  • Comparison of false positive rates by arm and by density group(3 and 6 years)
  • Comparison of attendance to mammography screening by arm and by density group.(1, 2, 3, 4, 5 and 6 year)
  • Comparison of cumulative incidence of breast cancer cases by arm and by density group.(3 and 6 years)

研究者

发起方
Cancer Prevention and Research Institute, Italy
申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验